Why is an IABP not the Answer to Cardiogenic Shock after Percutaneous Coronary Intervention? Is it that Noradrenaline helps, Especially by Improving the RV Function in Addition to LV Function? A View Point

Prabha Nini Gupta; Ullas R Mullamalla; Praveen Velappan; Gopakumar KS; Faeez Mohamad Ali; B Krishana Kumar; Krishna Kumar P

doi:10.4172/2329-6925.1000220

Awards Nomination 20+ Million Readerbase

Google Scholar citation report

Citations : 558

Journal of Vascular Medicine & Surgery received 558 citations as per Google Scholar report

Journal of Vascular Medicine & Surgery peer review process verified at publons

25+ Million Website Visitors

Indexed In

Open J Gate
Academic Keys
RefSeek
Hamdard University
EBSCO A-Z
OCLC- WorldCat
Publons
Euro Pub
Google Scholar

Useful Links

Share This Page

Journal Flyer

Tweets by vascular_123

Open Access Journals

Abstract

Why is an IABP not the Answer to Cardiogenic Shock after Percutaneous Coronary Intervention? Is it that Noradrenaline helps, Especially by Improving the RV Function in Addition to LV Function? A View Point

Prabha Nini Gupta, Ullas R Mullamalla, Praveen Velappan, Gopakumar KS, Faeez Mohamad Ali, B Krishana Kumar and Krishna Kumar P

We review the role of noradrenaline in cardiogenic shock. We describe our experience with the same after percutaneous coronary intervention, mostly primary angioplasty
The side effects of noradrenaline, the results of the SOAP 2 and the IABP Shock trial are also discussed. Noradrenaline is surprisingly a useful drug. So we want to share our experience with it.